Find Clinical Drug Pipeline Developments & Deals for Paclitaxel

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GEN-1,Carboplatin,Paclitaxel

            Therapeutic Area: Oncology Product Name: GEN-1

            Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Lincoln Park Capital

            Deal Size: $25.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement September 08, 2020

            Details:

            Capital received from the stock purchase agreement will be used in to advance its product pipeline including OVATION 2 Study and for general corporate purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Paclitaxel

            Therapeutic Area: Oncology Product Name: LiPax

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 08, 2020

            Details:

            In the study, LiPax was well tolerated. No significant adverse events were observed, and patients’ urinary health related quality of life was maintained during and after installation of LiPax, as measured by patient reported outcomes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Paclitaxel,Encequidar

            Therapeutic Area: Oncology Product Name: Oraxol

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 01, 2020

            Details:

            The Oral Paclitaxel NDA submission is supported by data from a single pivotal Phase III study of Oral Paclitaxel for the treatment of metastatic breast cancer.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AsiDNA,Carboplatin,Paclitaxel

            Therapeutic Area: Oncology Product Name: AsiDNA

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 27, 2020

            Details:

            DRIIV was instrumental in demonstrating a good safety profile and activity via IV route and in determining the active dose used today in the ongoing DRIIV-1b and REVOCAN studies of AsiDNA™ in combination with chemotherapy and PARP inhibitors .

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ofranergene obadenovec,Paclitaxel

            Therapeutic Area: Oncology Product Name: VB-111

            Highest Development Status: Phase III Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 12, 2020

            Details:

            Data Safety Monitoring Committee has completed its second, pre-planned interim analysis of OVAL Phase 3 study investigating ofranergene obadenovec in patients with platinum-resistant ovarian cancer, and unanimously recommended that the study continue as planned.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PRS-343,Ramucirumab,Paclitaxel

            Therapeutic Area: Oncology Product Name: PRS-343

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Eli Lilly

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 10, 2020

            Details:

            Lilly to supply Pieris with ramucirumab for the study as well as collaborate on data from the trial. Pieris is working towards initiation of a phase 2 single-arm combination study for the second-line treatment of HER2-positive gastric cancer later this year.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Paclitaxel,Oraxol

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sagard Healthcare Royalty Partners

            Deal Size: $50.0 million Upfront Cash: Undisclosed

            Deal Type: Financing August 06, 2020

            Details:

            The Company expects the proceeds from the financing will be used to fund the commercial launch of oral paclitaxel and encequidar (Oral Paclitaxel), ongoing pipeline development, manufacturing infrastructure, and working capital and general corporate purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Atezolizumab,Paclitaxel

            Therapeutic Area: Oncology Product Name: Tecentriq

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 06, 2020

            Details:

            The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoint of OS and data were immature at time of analysis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sugemalimab,Carboplatin,Paclitaxel

            Therapeutic Area: Oncology Product Name: CS1001

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 06, 2020

            Details:

            CS1001-302 is the first randomized double-blind phase III clinical trial of anti-PD-L1 monoclonal antibody combined with chemotherapy as a first-line treatment in patients with stage IV squamous and non-squamous non-small cell lung cancer (NSCLC) histological subtypes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Nivolumab,Bevacizumab,Paclitaxel

            Therapeutic Area: Oncology Product Name: Opdivo

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable August 03, 2020

            Details:

            This study is a multi-center, randomized, double-blind, placebo-controlled Phase III clinical study evaluating Opdivo in combination treatment with bevacizumab and chemotherapy versus placebo in combination with bevacizumab and chemotherapy.

            PharmaCompass